Samenvatting: GENESIS Pharma breidt strategisch commercieel partnerschap met Alnylam Pharmaceuticals voor RNAi-therapieën uit naar de Scandinavische regio

Key Takeaway: GENESIS Pharma is expanding its strategic commercial partnership with Alnylam Pharmaceuticals to include RNAi therapies in the Scandinavian region. This move aims to enhance the availability of innovative treatments in this market. The partnership reflects a growing interest in RNAi therapies and their potential impact on healthcare in Scandinavia.